Skip to main content

Table 3 The comparison of Cox regression of RFS between chart review and algorithm determined cohort

From: New method for determining breast cancer recurrence-free survival using routinely collected real-world health data

Variable

 

Chart view

HR (95% CI)

P-value

High-accuracy

HR (95% CI)

P-value

High-PPV

HR (95% CI)

P-value

High-sensitivity

HR (95% CI)

P-value

Age (year)

 <  = 35

Reference

0.124

Reference

0.123

Reference

0.125

Reference

0.162

36–40

1.51 (0.89–2.57)

1.62 (0.92–2.84)

1.42 (0.78–2.57)

1.39 (0.85–2.27)

41–55

0.92 (0.51–1.66)

0.87 (0.47–1.6)

0.83 (0.44–1.6)

0.75 (0.44–1.29)

 >  = 56

0.66 (0.33–1.32)

0.7 (0.35–1.4)

0.53 (0.25–1.16)

0.72 (0.4–1.31)

Tumor stage*

0-I

Reference

 < 0.0001

Reference

 < 0.0001

Reference

 < 0.0001

Reference

 < 0.0001

II

1.83 (0.82–4.06)

2.92 (1.08–7.91)

1.84 (0.71–4.78)

2.3 (1.09–4.87)

III

7.19 (3.24–15.92)

11.83 (4.38–31.91)

8.62 (3.37–22.03)

8.19 (3.85–17.43)

ER status

Negative

Reference

0.622

Reference

0.181

Reference

0.397

Reference

0.229

Positive

0.87 (0.5–1.52)

0.69 (0.41–1.19)

0.77 (0.43–1.4)

0.74 (0.45–1.21)

PR status

Negative

Reference

0.199

Reference

0.074

Reference

0.672

Reference

0.31

Positive

0.71 (0.43–1.19)

0.63 (0.38–1.05)

0.89 (0.51–1.55)

0.79 (0.49–1.25)

HER2 status*

Negative

Reference

0.003

Reference

0.003

Reference

0.007

Reference

0.016

Positive

0.48 (0.3–0.77)

0.48 (0.3–0.77)

0.5 (0.3–0.83)

0.6 (0.4–0.91)

Histology

Ductal

Reference

0.182

Reference

0.058

Reference

0.102

Reference

0.102

Lobular

0.52 (0.2–1.36)

0.9 (0.37–2.2)

0.97 (0.39–2.43)

0.57 (0.24–1.38)

Other

1.51 (0.75–3.01)

2.17 (1.13–4.17)

2.16 (1.06–4.41)

1.67 (0.9–3.08)

Tumor grade

1

Reference

0.379

Reference

0.052

Reference

0.065

Reference

0.101

2

1.92 (0.75–4.93)

2.19 (0.76–6.3)

1.68 (0.58–4.88)

1.83 (0.77–4.38)

3

1.92 (0.75–4.93)

3.12 (1.0–8.86)

2.66 (0.93–7.63)

2.38 (0.99–5.66)

Hormone therapy*

No

Reference

0.013

Reference

0.002

Reference

0.016

Reference

0.05

Yes

0.74 (0.4–1.36)

1.22 (0.64–2.36)

0.84 (0.42–1.67)

0.99 (0.57–1.72)

Unknown

3.65 (1.35–9.81)

5.14 (2.06–12.83)

4.34 (1.47–12.79)

2.72 (1.16–6.35)

Radiotherapy*

No

Reference

0.017

Reference

0.002

Reference

0.030

Reference

0.058

Yes

1.01 (0.55–1.87)

1.03 (0.55–1.96)

0.88 (0.44–1.75)

0.97 (0.56–1.69)

Unknown

0.25 (0.1–0.66)

0.22 (0.09–0.52)

0.24 (0.09–0.7)

0.38 (0.17–0.85)

Chemotherapy

No

Reference

0.158

Reference

0.216

Reference

0.258

Reference

0.001

Yes

0.57 (0.27–1.24)

0.57 (0.24–1.38)

0.59 (0.24–1.47)

0.33 (0.17–0.63)^

Year of diagnosis

2007–2009

Reference

0.784

Reference

0.228

Reference

0.394

Reference

0.188

2010–2012

1.29 (0.63–2.63)

1.7 (0.82–3.52)

1.07 (0.48–2.39)

1.78 (0.96–3.31)

2013–2015

1.27 (0.56–2.88)

2.07 (0.9–4.75)

1.55 (0.63–3.79)

1.71 (0.83–3.54)

  1. HR hazard ratio, CI confidence interval, PPV positive predictive value, ER estrogen receptor, PR progesterone receptor, HER2 Human Epidermal growth factor Receptor 2
  2. * indicates that the variable was statistically significant (p-value < 0.05) based on chart review data
  3. ^ indicates that the variable was statistically significant (p-value < 0.05) based on high-sensitivity algorithm estimated data